As partners of our internationally operating clients, we support the successful market access especially of treatments for rare diseases, of ATMPs or of products which set new therapy standards, both on a strategic and operational level.
Our whitepaper (re-)analyzes the implications of the newly defined EU HTA framework and presentoperative, strategic, and structural success factors to optimally prepare for and handle the new process.
Our exclusive white paper provides a comprehensive analysis to derive key considerations for the strategic challenges for gene therapies in Germany, with a focus on pricing and reimbursement
With our longstanding AMNOG-expertise we support DiGA-providers with a customized market access strategy – all the way from the development of the value story to successful price negotiations.
